129 related articles for article (PubMed ID: 28103033)
1. Design, Synthesis, and Biological Evaluation of Small, High-Affinity Siglec-7 Ligands: Toward Novel Inhibitors of Cancer Immune Evasion.
Prescher H; Frank M; Gütgemann S; Kuhfeldt E; Schweizer A; Nitschke L; Watzl C; Brossmer R
J Med Chem; 2017 Feb; 60(3):941-956. PubMed ID: 28103033
[TBL] [Abstract][Full Text] [Related]
2. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
[TBL] [Abstract][Full Text] [Related]
3. Siglec-7 engagement by GBS β-protein suppresses pyroptotic cell death of natural killer cells.
Fong JJ; Tsai CM; Saha S; Nizet V; Varki A; Bui JD
Proc Natl Acad Sci U S A; 2018 Oct; 115(41):10410-10415. PubMed ID: 30254166
[TBL] [Abstract][Full Text] [Related]
4. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
5. Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells.
Yoshimura A; Asahina Y; Chang LY; Angata T; Tanaka H; Kitajima K; Sato C
J Biol Chem; 2021; 296():100477. PubMed ID: 33640457
[TBL] [Abstract][Full Text] [Related]
6. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
[TBL] [Abstract][Full Text] [Related]
7. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
8. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.
Avril T; North SJ; Haslam SM; Willison HJ; Crocker PR
J Leukoc Biol; 2006 Oct; 80(4):787-96. PubMed ID: 16857734
[TBL] [Abstract][Full Text] [Related]
9. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.
Tao L; Wang S; Yang L; Jiang L; Li J; Wang X
Clin Exp Immunol; 2020 Aug; 201(2):161-170. PubMed ID: 32319079
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation-mediated Siglec-7 regulation in natural killer cells via two 5' promoter CpG sites.
Huang HT; Su SC; Chiou TJ; Lin YH; Shih YC; Wu YX; Fan TH; Twu YC
Immunology; 2020 May; 160(1):38-51. PubMed ID: 32027025
[TBL] [Abstract][Full Text] [Related]
11. Deacetylated sialic acids modulates immune mediated cytotoxicity via the sialic acid-Siglec pathway.
Grabenstein S; Barnard KN; Anim M; Armoo A; Weichert WS; Bertozzi CR; Parrish CR; Willand-Charnley R
Glycobiology; 2021 Nov; 31(10):1279-1294. PubMed ID: 34192335
[TBL] [Abstract][Full Text] [Related]
12. Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities.
Shao JY; Yin WW; Zhang QF; Liu Q; Peng ML; Hu HD; Hu P; Ren H; Zhang DZ
Scand J Immunol; 2016 Sep; 84(3):182-90. PubMed ID: 27312286
[TBL] [Abstract][Full Text] [Related]
13. On-chip synthesis and screening of a sialoside library yields a high affinity ligand for Siglec-7.
Rillahan CD; Schwartz E; Rademacher C; McBride R; Rangarajan J; Fokin VV; Paulson JC
ACS Chem Biol; 2013 Jul; 8(7):1417-22. PubMed ID: 23597400
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a new sialic acid binding region that regulates Siglec-7.
Yamakawa N; Yasuda Y; Yoshimura A; Goshima A; Crocker PR; Vergoten G; Nishiura Y; Takahashi T; Hanashima S; Matsumoto K; Yamaguchi Y; Tanaka H; Kitajima K; Sato C
Sci Rep; 2020 May; 10(1):8647. PubMed ID: 32457377
[TBL] [Abstract][Full Text] [Related]
15. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells.
Kawasaki Y; Ito A; Withers DA; Taima T; Kakoi N; Saito S; Arai Y
Glycobiology; 2010 Nov; 20(11):1373-9. PubMed ID: 20663960
[TBL] [Abstract][Full Text] [Related]
16. A Sulfonamide Sialoside Analogue for Targeting Siglec-8 and -F on Immune Cells.
Nycholat CM; Duan S; Knuplez E; Worth C; Elich M; Yao A; O'Sullivan J; McBride R; Wei Y; Fernandes SM; Zhu Z; Schnaar RL; Bochner BS; Paulson JC
J Am Chem Soc; 2019 Sep; 141(36):14032-14037. PubMed ID: 31460762
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Receptors and Checkpoints in Human NK Cells, Implications for the Immunotherapy of Cancer.
Sivori S; Della Chiesa M; Carlomagno S; Quatrini L; Munari E; Vacca P; Tumino N; Mariotti FR; Mingari MC; Pende D; Moretta L
Front Immunol; 2020; 11():2156. PubMed ID: 33013909
[TBL] [Abstract][Full Text] [Related]
18. Impact of polysialylated CD56 on natural killer cell cytotoxicity.
Moebius JM; Widera D; Schmitz J; Kaltschmidt C; Piechaczek C
BMC Immunol; 2007 Aug; 8():13. PubMed ID: 17683591
[TBL] [Abstract][Full Text] [Related]
19. Unraveling Molecular Recognition of Glycan Ligands by Siglec-9 via NMR Spectroscopy and Molecular Dynamics Modeling.
Atxabal U; Nycholat C; Pröpster JM; Fernández A; Oyenarte I; Lenza MP; Franconetti A; Soares CO; Coelho H; Marcelo F; Schubert M; Paulson JC; Jiménez-Barbero J; Ereño-Orbea J
ACS Chem Biol; 2024 Feb; 19(2):483-496. PubMed ID: 38321945
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7.
Wisnovsky S; Möckl L; Malaker SA; Pedram K; Hess GT; Riley NM; Gray MA; Smith BAH; Bassik MC; Moerner WE; Bertozzi CR
Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33495350
[No Abstract] [Full Text] [Related]
[Next] [New Search]
